"10.1371_journal.pone.0132568","plos one","2015-07-24T00:00:00Z","Christine Rotonda; Amélie Anota; Mariette Mercier; Bérangère Bastien; Gisèle Lacoste; Jean-Marc Limacher; Elisabeth Quoix; Franck Bonnetain","National Quality of Life in Oncology Platform, Nancy, France; INSERM, CIC-EC CIE6, Nancy, France; CHU Nancy, Clinical Epidemiology and Evaluation Department, Nancy, France; Université de Franche-Comté, EA 3181, Besançon, France; CHU Besançon, Methodological and quality of life unit in oncology, Besançon, France; Transgene SA, Illkirch, France; Hôpitaux Universitaires de Strasbourg, Strasbourg, France","Conceived and designed the experiments: BB GL JML EQ. Performed the experiments: BB GL JML EQ. Analyzed the data: CR AA MM FB. Contributed reagents/materials/analysis tools: CR AA FB. Wrote the paper: CR AA MM BB GL JML EQ FB.","This study was supported by Transgene SAS. This work is a contribution to ADNA (Advanced Diagnostics for New Therapeutic Approaches), a program dedicated to personalized medicine, coordinated by Institut Mérieux and supported by the French public agency Bpifrance. GL, BB and JML are full time employees of Transgene SA. There are no patents related to the quality of life data presented in the publication, however. TG4010 is a product in development, not marketed so far and protected by a family of patents. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","07","Christine Rotonda","CR",8,TRUE,4,4,4,8,TRUE,TRUE,FALSE,0,NA,FALSE
